ROCHE HOLDING AG-BR (RHO.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:RHO - CH0012032113 - Common Stock
RHO.DE Key Statistics, Chart & Performance
The current stock price of RHO.DE is 350 EUR. In the past month the price increased by 13.86%.
RHO.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1SAN.MI | SANOFI | 11.54 | 213.66B | ||
| SAN.PA | SANOFI | 11.36 | 210.27B | ||
| SNW.DE | SANOFI | 11.35 | 209.50B | ||
| MRK.DE | MERCK KGAA | 13.17 | 48.83B | ||
| UCB.BR | UCB SA | 36.29 | 45.32B | ||
| UNC.DE | UCB SA | 34.83 | 43.49B | ||
| BAYN.DE | BAYER AG-REG | 5.17 | 27.10B | ||
| 1BAYN.MI | BAYER AG-REG | 5.15 | 27.01B | ||
| IPN.PA | IPSEN | 12.38 | 10.65B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.76 | 10.61B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.74 | 9.34B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.63 | 8.95B |
Related stock screener links
About RHO.DE
Company Profile
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Company Info
ROCHE HOLDING AG-BR
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
Phone: 41616881111
ROCHE HOLDING AG-BR / RHO.DE FAQ
Can you describe the business of ROCHE HOLDING AG-BR?
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Can you provide the latest stock price for ROCHE HOLDING AG-BR?
The current stock price of RHO.DE is 350 EUR. The price increased by 0.81% in the last trading session.
Does ROCHE HOLDING AG-BR pay dividends?
ROCHE HOLDING AG-BR (RHO.DE) has a dividend yield of 3.11%. The yearly dividend amount is currently 10.87.
How is the ChartMill rating for ROCHE HOLDING AG-BR?
RHO.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of RHO stock?
ROCHE HOLDING AG-BR (RHO.DE) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the PE ratio for RHO stock?
The PE ratio for ROCHE HOLDING AG-BR (RHO.DE) is 16.53. This is based on the reported non-GAAP earnings per share of 21.18 and the current share price of 350 EUR.
Can you provide the market cap for ROCHE HOLDING AG-BR?
ROCHE HOLDING AG-BR (RHO.DE) has a market capitalization of 283.24B EUR. This makes RHO.DE a Mega Cap stock.
RHO.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RHO.DE.
RHO.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RHO.DE. RHO.DE scores excellent on profitability, but there are some minor concerns on its financial health.
RHO.DE Financial Highlights
Over the last trailing twelve months RHO.DE reported a non-GAAP Earnings per Share(EPS) of 21.18. The EPS increased by 5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| Debt/Equity | 1.06 |
RHO.DE Forecast & Estimates
27 analysts have analysed RHO.DE and the average price target is 349.07 EUR. This implies a price decrease of -0.27% is expected in the next year compared to the current price of 350.
For the next year, analysts expect an EPS growth of 5.57% and a revenue growth 2.13% for RHO.DE